SCHEMBL22166296

SCHEMBL22166296

CCCC(C)C(NCC)C(C)C

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22220981 0.82 METAP1 (0.32) METAP1
SCHEMBL18656053 0.74
SCHEMBL19063319 0.74 METAP1 (0.33) METAP1
SCHEMBL24722286 0.74 METAP1 (0.33) METAP1
SCHEMBL20714587 0.70 METAP1 (0.31) METAP1
SCHEMBL1688119 0.70 METAP1 (0.31) METAP1
SCHEMBL19502445 0.69 TSHR (0.33)
SCHEMBL18030194 0.69 TSHR (0.33)
SCHEMBL19485950 0.69 TSHR (0.32)
SCHEMBL18480730 0.68 METAP1 (0.30) METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10695436-B2 Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists NANOPHARMACEUTICALS, LLC (US) 2020-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10695436-B2 Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists THRA, CD44, ITGAV METAP1 3217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.